NASDAQ:SNGX Soligenix (SNGX) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free SNGX Stock Alerts $0.60 -0.01 (-1.64%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.59▼$0.6150-Day Range$0.57▼$0.8252-Week Range$0.38▼$4.20Volume137,602 shsAverage Volume106,621 shsMarket Capitalization$6.31 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Soligenix alerts: Email Address Soligenix MarketRank™ Stock AnalysisAnalyst Rating0.00 Rating ScoreUpside/Downside400.0% Upside$3.00 Price TargetShort InterestHealthy0.65% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.03Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.81 to ($0.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.81 out of 5 stars 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Soligenix has a forecasted upside of 400.0% from its current price of $0.60.Amount of Analyst CoverageSoligenix has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.65% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently decreased by 80.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNGX. Previous Next 2.8 News and Social Media Coverage News SentimentSoligenix has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Soligenix this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for SNGX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.36% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 3.60% of the stock of Soligenix is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Soligenix are expected to decrease in the coming year, from $0.81 to ($0.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soligenix is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soligenix is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoligenix has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Soligenix Stock (NASDAQ:SNGX)Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase IIa clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Read More SNGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNGX Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comZacks Small Cap Weighs in on Soligenix, Inc.'s FY2024 Earnings (NASDAQ:SNGX)March 23, 2024 | americanbankingnews.comSoligenix, Inc. Expected to Earn Q1 2024 Earnings of ($0.20) Per Share (NASDAQ:SNGX)March 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 22, 2024 | americanbankingnews.comSoligenix (NASDAQ:SNGX) Share Price Crosses Above Two Hundred Day Moving Average of $0.61March 20, 2024 | finance.yahoo.comSNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…March 15, 2024 | investorplace.comSNGX Stock Earnings: Soligenix Beats EPS, Beats Revenue for Q4 2023March 15, 2024 | benzinga.comRecap: Soligenix Q4 EarningsMarch 15, 2024 | prnewswire.comSoligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…February 8, 2024 | finance.yahoo.comSoligenix Announces Formation of Behçet's Disease Medical Advisory BoardFebruary 1, 2024 | thestreet.comSoligenix Inc.January 26, 2024 | finanznachrichten.deSoligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVJanuary 26, 2024 | finance.yahoo.comSoligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJanuary 25, 2024 | finance.yahoo.comSoligenix to Present at The Microcap ConferenceJanuary 10, 2024 | finance.yahoo.comSNGX: Phase 2a Psoriasis Trial Achieves Clinical Success…January 8, 2024 | marketwatch.comSoligenix Shares Rise 8% After SGX945 Gets FDA Fast Track DesignationJanuary 8, 2024 | finance.yahoo.comFDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseJanuary 4, 2024 | markets.businessinsider.comSoligenix Reports Positive Preliminary Results From Phase 2a Study Of SGX302 In PsoriasisJanuary 4, 2024 | finance.yahoo.comSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisJanuary 2, 2024 | marketwatch.comSoligenix Shares Rise 19% After Vaccine Trial Shows Protection Against Two VirusesJanuary 2, 2024 | markets.businessinsider.comSoligenix Reports Preclinical Efficacy Of Bivalent Vaccine Against Two VirusesJanuary 2, 2024 | msn.comWhy Is Rare Disease Focused Soligenix Stock Soaring Today?January 2, 2024 | finance.yahoo.comSoligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesDecember 9, 2023 | finance.yahoo.comHere's Why We Think Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation Looks FairDecember 1, 2023 | finance.yahoo.com"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug DiscoveryNovember 30, 2023 | msn.comWhy Is This Rare Disease-Focused Soligenix Stock Trading Over 200% Today?November 30, 2023 | investorplace.comWhy Is Soligenix (SNGX) Stock Up 285% Today?See More Headlines Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today3/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SNGX CUSIPN/A CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees13Year Founded1987Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+400.0%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E Ratio0.74 P/E GrowthN/ANet Income$-6,140,000.00 Net Margins-731.94% Pretax Margin-942.67% Return on Equity-251.07% Return on Assets-49.94% Debt Debt-to-Equity Ratio0.40 Current Ratio1.55 Quick Ratio1.52 Sales & Book Value Annual Sales$840,000.00 Price / Sales7.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book2.50Miscellaneous Outstanding Shares10,520,000Free Float10,381,000Market Cap$6.31 million OptionableNot Optionable Beta1.83 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Christopher J. Schaber Ph.D. (Age 58)Chairman of the Board of Directors, CEO & President Comp: $625kMr. Jonathan L. Guarino CPA (Age 51)CGMA, Senior VP, CFO & Corporate Secretary Comp: $309.4kDr. Oreola Donini Ph.D. (Age 52)Senior VP & Chief Scientific Officer Comp: $342.31kDr. Richard C. Straube M.D. (Age 72)MSc., Senior VP & Chief Medical Officer Comp: $212.2kKey CompetitorsOragenicsNYSE:OGENGT BiopharmaNASDAQ:GTBPPulmatrixNASDAQ:PULMKinetaNASDAQ:KAYumanity TherapeuticsNASDAQ:YMTXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 24,100 shares on 3/11/2024Ownership: 0.484%Vanguard Group Inc.Bought 24,100 shares on 2/15/2024Ownership: 0.483%View All Institutional Transactions SNGX Stock Analysis - Frequently Asked Questions What is Soligenix's stock price target for 2024? 0 Wall Street research analysts have issued 1-year price objectives for Soligenix's stock. Their SNGX share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for SNGX or view top-rated stocks among Wall Street analysts. How have SNGX shares performed in 2024? Soligenix's stock was trading at $0.7572 at the beginning of the year. Since then, SNGX stock has decreased by 20.8% and is now trading at $0.60. View the best growth stocks for 2024 here. Are investors shorting Soligenix? Soligenix saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 67,700 shares, a drop of 80.9% from the February 29th total of 354,500 shares. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.7% of the shares of the company are short sold. View Soligenix's Short Interest. When is Soligenix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our SNGX earnings forecast. How were Soligenix's earnings last quarter? Soligenix, Inc. (NASDAQ:SNGX) posted its quarterly earnings data on Friday, March, 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.03. The biopharmaceutical company had revenue of $0.25 million for the quarter, compared to analysts' expectations of $0.20 million. Soligenix had a negative trailing twelve-month return on equity of 251.07% and a negative net margin of 731.94%. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM). Who are Soligenix's major shareholders? Soligenix's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.48%) and Vanguard Group Inc. (0.48%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube. View institutional ownership trends. How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNGX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.